Straits Times Index
3,323.22 -3.06 (-0.09%) Nikkei
39,726.39 +553.24 (+1.41%) Hang Seng
18,049.95 -22.95 (-0.13%) FTSE 100
8,247.79 -33.76 (-0.41%) Bitcoin USD
61,970.58 +1,147.16 (+1.89%) CMC Crypto 200
1,288.12 +39.00 (+3.12%)
EyePoint Pharmaceuticals Inc (PV3B.BE)
| Previous close | 7.94 |
| Open | 7.96 |
| Bid | 7.50 x N/A |
| Ask | 7.93 x N/A |
| Day's range | 7.78 - 7.99 |
| 52-week range | 5.35 - 30.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksIntra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
GlobeNewswireEyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R&D Day on Wednesday, June 26, 2024 from 8:00 a.m. to 9:30 a.m. ET. The R&D Day will feature presentations and a roundtable discussion from key opinion leader (KOL) guest speakers Carl D. Regillo, M.D., F
- GlobeNewswire
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an
